Ascendis Pharma Wins FDA Clearance for First Weekly Achondroplasia Treatment in Children
Ascendis Pharma wins FDA approval for YUVIWEL, the first once-weekly treatment for pediatric achondroplasia. The therapy offers improved dosing convenience over existing options.
ASNDFDA approvalaccelerated approval